医用生物蛋白胶及其主体成分纤维蛋白原的免疫原性研究

研究医用生物蛋白胶及其主体成分纤维蛋白原的潜在免疫原性。采用SDS-PAGE电泳、Western blot分离确定主体胶成分中的纤维蛋白原蛋白,建立间接ELISA法检测抗体条件;新西兰白兔创伤实验及BALB/c小鼠实验考察医用生物蛋白胶及纤维蛋白原的免疫原性。结果表明,生物蛋白胶主体成分以0.5μg/ml包被时,可有效检测抗纤维蛋白原抗体。新西兰白兔创伤实验中,实验组兔血清1周后出现抗体,2周后抗体水平明显升高,6周后抗体水平下降,呈先升后降的动态变化趋势;小鼠实验中,NBT试验未发现阳性中性粒细胞,MTT检测到T细胞呈现弱增殖能力。研究表明,医用生物蛋白胶主体胶成分中的纤维蛋白原在兔出现一过性抗体,医用生物蛋白胶对小鼠未表现出明显的免疫原性。

Immunogenicity of fibrin sealant and its main component fibrinogen

To investigate the potential immunogenicity of fibrin sealant and its main component figrinogen,the fibrinogen protein was separated from the major component of fibrin sealant by SDS-PAGE and identified by Western blotting,indirect ELISA was used for the detection of specific antibodies in sera,and the immunogenicity of fibrin sealant and fibrinogen was investigated by means of the injury experiment in New Zealand rabbits and the medication experiment in BALB/c mice。It was found that anti-fibrinogen antibody could be detected,when 0.5 μg/ml of the main component in fibrin sealant was used as the coating antigen. In case of the injury experiment in New Zealand rabbits,the specific antibodies appeared after one week,significantly rose up after 2 weeks,and dropped 6 weeks later,with dynamic tendency of initial rising and later dropping. In the medication experiment on BALB/c mice,no positive cell with dark blue formazan could be found in NBT test and the MTT test showed a weakly proliferative ability of T cells in mice. In a word,these results indicate that fibrinogen in the main components of fibrin sealant only induces a temporary rise of specific antibodies in rabbits and no apparent immunogenicity can be found in mice.